[EGF receptor, a prognostic factor in epidermoid cancers of the upper aerodigestive tracts].
EGFR was determined, before treatment; in tumors biopsies obtained from 109 consecutive patients with head and neck cancer (100 men and nine women), using iodine labelled recombinant EGF. The median age of the study population was 60 years. EGFR levels varied from 2 to 2302 fmol/mg membrane protein (median 71). There was a significant difference of distribution for EGFR levels between stages I and II tumors and stages III and IV tumors (P = 0.03). The EGFR cut-off value for overall survival was 120 fmol/mg protein and the median follow-up was 18 months (3-35) EGFR overexpression was associated with shorter relapse-free (P = 0.0125) and overall survival (P = 0.028). By multivariate analysis the only significant variables were EGFR for relapse-free survival and tumor staging and EGFR for overall survival. Analyzed in 60 patients treated by first-line chemotherapy CDDP-5FU, the longest survival was achieved for patients who had a complete response to chemotherapy and the lowest EGFR levels (P = 0.018). EGFR expression in the primary tumor allows survival among first line chemotherapy responder categories to be discriminated.
Formento
J L
JL
Centre Antonine-Lacassagne, Nice, France.
Francoual
M
M
Ramaioli
A
A
Dassonville
O
O
Santini
J
J
Demard
F
F
Schneider
M
M
Milano
G
G
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis*; D002294:Carcinoma, Squamous Cell / Q000737:chemistry* / Q000401:mortality / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D066246:ErbB Receptors / Q000032:analysis*; D005260:Female; D006258:Head and Neck Neoplasms / Q000737:chemistry* / Q000401:mortality / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D011379:Prognosis; D011446:Prospective Studies; D012008:Recurrence; D016019:Survival Analysis
D014408:Biomarkers, Tumor; D066246:ErbB Receptors
Le récepteur d'EGF, facteur de pronostic dans les cancers épidermoïdes des voies aérodigestives supérieures.